Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Knight-Swift Transportation Holdings Inc. (KNX) vs Novo Nordisk A/S (NVO) Price & Performance

Knight-Swift Transportation Holdings Inc.Trade
Novo Nordisk A/STrade

Price performance (Past 24H)

Key statistics

Knight-Swift Transportation Holdings Inc. vs Novo Nordisk A/S — how do they compare? Knight-Swift Transportation Holdings Inc. trades at $64.47 (market cap $10.59B), while Novo Nordisk A/S trades at $38.64 (market cap $165.31B). The key difference: Novo Nordisk A/S is far larger — about 15.6× Knight-Swift Transportation Holdings Inc.'s market cap, and Novo Nordisk A/S pays the higher dividend (4.71%). Which is the better fit depends on your goals — on Pluang, investors hold Knight-Swift Transportation Holdings Inc. for 1 Days and Novo Nordisk A/S for 116 Days on average.

KNXNVO
Market Cap
$10.59B$165.31B
Volume
2,972,51111,432,838
Sector
IndustrialsHealth
52-Week High
$82.45$63.98
52-Week Low
$41.68$35.29
Typical Hold Time
1 Days116 Days
Enterprise Value
$13.09B$179.56B
Dividend Yield
1.23%4.71%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Knight-Swift Transportation Holdings Inc.

No Aura AI signal available yet.

Novo Nordisk A/S

Novo Nordisk (NVO) trades at $38.18, down 0.21% with a bearish technical signal. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and robust profitability (35.35% net margin, 59.82% ROE). Recent news highlights pipeline developments including Wegovy pill data and a $4 billion licensing deal, though the FDA extended review of its hemophilia drug. Cash flow remains positive at $10.81B for 2025, supporting dividend payments.

NVO presents a compelling value opportunity with a 9.66 P/E ratio and 17% upside to the $44.67 consensus target. However, competitive pressure from Eli Lilly's obesity drug pipeline and regulatory delays pose near-term risks. Analyst sentiment is bullish (59% buy ratings), but investors should monitor Q3 2026 earnings against the 0.753 EPS expectation for confirmation of growth trajectory.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

KNX

No sentiment data available yet.

NVO
96% Buy4% Sell
Avg holding period · 116 Days

Top news

Latest headlines on both assets

About Knight-Swift Transportation Holdings Inc.

Knight-Swift provides truckload, less-than-truckload, logistics, and freight management services. It operates a large transportation network across North America.

Read more on KNX →

About Novo Nordisk A/S

With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Read more on NVO →